US OptionsDetailed Quotes
XBIT240816P5000
- 0.10
- -0.05-33.33%
15min DelayClose Jul 25 09:51 ET
0.10High0.10Low
0.10Open0.15Pre Close3 Volume9 Open Interest5.00Strike Price30.00Turnover160.45%IV29.70%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.1445Delta0.0816Gamma27.88Leverage Ratio-0.0141Theta-0.0007Rho-4.03Eff Leverage0.0040Vega
XBiotech Stock Discussion
XBiotech (NASDAQ: XBIT) recently announced promising data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Named 1-BETTER, this study focused on evaluating Natrunix, an anti-interleukin-1alpha antibody, in combination with a well-established chemotherapy regimen comp...
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech (NASDAQ: XBIT) announced promising results from its Phase 1/2 trial for advanced pancreatic cancer treatment using Natrunix in combination with a standard chemotherapy regimen. The study, titled 1-BETTER, enrolled 65 subjects who received either the Natrunix combination or a placebo. Key findings include a 28% reduction in signif...
Where can check this information?
If I have 10 share....
Where is the money? 🧐
No comment yet